Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
7.40
Nov 18 • 6:07 AM ET Dollar change+0.07 Percentage change(0.95%)
Index
-
Market Cap
117.52M
Enterprise Value
-14.19M
Income
-128.30M
Sales
0.00M
Book/sh
6.58
Cash/sh
8.31
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
92
IPO
Apr 17, 2014
P/E
-
Forward P/E
-
PEG
-
P/S
-
P/B
1.12
P/C
0.89
P/FCF
-
EV/EBITDA
-
EV/Sales
-
Quick Ratio
4.28
Current Ratio
4.28
Debt/Eq
0.00
LT Debt/Eq
0.00
Option/Short
Yes / Yes
EPS (ttm)
-4.48
EPS next Y
-2.38
EPS next Q
-0.82
EPS this Y
39.55%
EPS next Y
36.47%
EPS next 5Y
26.21%
EPS past 3/5Y
45.16% 25.99%
Sales past 3/5Y
- -
EPS Y/Y TTM
48.29%
Sales Y/Y TTM
-
EPS Q/Q
25.06%
Sales Q/Q
-
Insider Own
6.52%
Insider Trans
0.00%
Inst Own
90.83%
Inst Trans
12.49%
ROA
-144.86%
ROE
-223.18%
ROIC
-122.80%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
SMA20
-2.72%
SMA50
-11.66%
SMA200
-36.07%
Trades
Shs Outstand
15.88M
Shs Float
12.76M
52W High
17.43 -57.54%
52W Low
5.06 46.19%
Volatility
6.28% 7.25%
ATR (14)
0.55
RSI (14)
43.01
Beta
1.47
Rel Volume
0.06
Avg Volume
336.86K
Volume
992
Perf Week
-8.87%
Perf Month
-0.13%
Perf Quarter
-54.04%
Perf Half Y
-35.93%
Perf YTD
38.65%
Perf Year
-2.63%
Perf 3Y
-30.19%
Perf 5Y
-91.55%
Perf 10Y
-99.70%
Prev Close
7.33
Price
7.40
Change %
0.95%
Consensus
Strong Buy
Avg. Price Target
$42.55
Implied Upside
+475.0%
Analysts17incl. previous ratings
Rating Distribution15 Buy · 2 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Oct 23, 2026Initiated
CCantor Fitzgerald
Overweight
Aug 17, 2026Initiated
WWedbush
Outperform$45+508.1%
May 22, 2026Initiated
WWolfe Research
Outperform
Apr 17, 2026Initiated
SF logoSStifel
Buy$2.50-66.2%
Apr 15, 2026Downgrade
DD. Boral Capital
Buy → Hold
Mar 24, 2026Initiated
GGuggenheim
Buy$7-5.4%
Nov 07, 2025Initiated
RRoth Capital
Buy$3-59.5%
Sep 29, 2025Initiated
CChardan Capital Markets
Buy$13+75.7%
Mar 25, 2025Initiated
WWilliam Blair
Outperform
Nov 25, 2024Initiated
HH.C. Wainwright
Buy$10+35.1%
Immunic, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. It focuses on ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The firm's products include IMU-838, IMU-935, and IMU-856. The company was founded in May 2003 and is headquartered in New York, NY.
COO & PresidentMr. Jason Tardio M.B.A.
Chief Financial OfficerMr. Glenn Whaley CPA
CEO & DirectorMr. Erik Lundgren
Co-Founder & Chief Scientific OfficerDr. Hella Kohlhof
Vice President of Investor Relations & CommunicationsMs. Jessica Breu